Tarceva

Phase 3Small molecule

OOSI Pharmaceuticals

Tarceva is one of 386 small molecule programs targeting Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

385

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Lung AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Prostate CancerActive, not recruiting

GliomaPhase 1

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Esophageal CancerPhase 3

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Pancreatic AdenocarcinomaPhase 1

Active, not recruiting

Lung AdenocarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tarceva

OOSI Pharmaceuticals

Phase 3

1 2

Tecentriq

Roche

Preclinical

36 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer10 trials

Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer

Completed·OOlfred Hansen·Phase 2·NCT00888511·15 enrolled

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Completed·OOSI Pharmaceuticals·Phase 1·NCT00294736·57 enrolled

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed·OOSI Pharmaceuticals·Phase 2·NCT00072631·43 enrolled

Show 7 more trials

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Completed· Roche logo

Roche·Phase 2·NCT00095225·122 enrolled

Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer

Completed·WWeill Medical College of Cornell University·Phase 2·NCT00385996·22 enrolled

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Completed·OOSI Pharmaceuticals·Phase 2·NCT00085839·103 enrolled

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00871923·44 enrolled

Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer

Unknown status·GGrupo Gallego de Cancer de Pulmon·Phase 2·NCT00466284·46 enrolled

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·OOSI Pharmaceuticals·Phase 3·NCT00036647·731 enrolled

A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT00091663·5,000 enrolled

Pancreatic Cancer3 trials

Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

Terminated·IInstitut Català d'Oncologia·Phase 2·NCT01531712·6 enrolled

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Completed·OOSI Pharmaceuticals·Phase 3·NCT00040183·569 enrolled

Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

Completed·IIndiana University School of Medicine·Phase 1·NCT00243854·8 enrolled

Lung Cancer3 trials

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00043823·41 enrolled

A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer

Completed· Roche logo

Roche·Phase 3·NCT00047736

Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00063258·5 enrolled

Small Cell Lung Cancer2 trials

Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)

Completed·GGroupe Francais De Pneumo-Cancerologie··NCT00419042·100 enrolled

Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer

Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 1·NCT00707252·11 enrolled

Metastatic Colorectal Cancer2 trials

Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

Completed·SSamsung Medical Center·Phase 2·NCT03086538·29 enrolled

Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT00123851·32 enrolled

14 more indications

Pancreatic Adenocarcinoma1 trial

Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma

Completed·—·Phase 1·NCT00735306·12 enrolled

Elderly Patients1 trial

OSI-774 (Erlotinib, Tarceva) in Elderly Patients

Completed·MMontefiore Medical Center·Phase 2·NCT00200395·30 enrolled

Carcinoma1 trial

Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

Completed·IInstitut Claudius Regaud·N/A·NCT00144976·43 enrolled

Prostate Cancer1 trial

Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer

Completed·OOncology Specialists, S.C.·Phase 2·NCT00272038·29 enrolled

Lung Adenocarcinoma1 trial

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

Unknown status·FFirst Affiliated Hospital of Kunming Medical University·Phase 2·NCT02704767·60 enrolled

Chemotherapy1 trial

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Completed·OOSI Pharmaceuticals·Phase 2·NCT00294762·143 enrolled

MPA1 trial

A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions

Completed·QQuadras Scientific Solutions·Phase 4·NCT04145570·24 enrolled

Esophageal Cancer1 trial

Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer

Unknown status·WWenzhou Medical University·Phase 3·NCT00686114·344 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors

Completed·UUniversity of California, San Francisco·Phase 2·NCT00187486·66 enrolled

Renal Cell Carcinoma1 trial

A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma

Completed· Roche logo

Roche·Phase 2·NCT00081614·100 enrolled

Glioma1 trial

Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT00418327·48 enrolled

Breast Cancer1 trial

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00739063·11 enrolled

Solid Tumors1 trial

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

Withdrawn·AAbbott·Phase 1·NCT00754104

Glioblastoma1 trial

Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma

Completed·UUniversity of California, San Francisco·Phase 2·NCT00525525·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Tarceva. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tarceva compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tarceva. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OSI Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOSI Pharmaceuticals

Tarceva

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Cancer10 trials

Pancreatic Cancer3 trials

Lung Cancer3 trials

Small Cell Lung Cancer2 trials

Metastatic Colorectal Cancer2 trials

Pancreatic Adenocarcinoma1 trial

Elderly Patients1 trial

Carcinoma1 trial

Prostate Cancer1 trial

Lung Adenocarcinoma1 trial

Chemotherapy1 trial

MPA1 trial

Esophageal Cancer1 trial

Safety and Efficacy1 trial

Renal Cell Carcinoma1 trial

Glioma1 trial

Breast Cancer1 trial

Solid Tumors1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News